ARA-290: The 11-amino-acid peptide stripped from erythropoietin — engineered to heal nerves without making a single red blood cell

Erythropoietin has two jobs. The one everyone knows — making red blood cells — put EPO at the center of the biggest doping scandal in sports history. But EPO also protects damaged tissue: heart muscle after a heart attack, neurons after a stroke, nerve fibers after injury. For decades, researchers watched this second job with frustration. They could not give patients EPO for tissue repair without also pushing their red blood cell counts into dangerous territory — polycythemia, blood clots, cardiovascular death. The protective effects and the dangerous effects were locked inside the same molecule.

In 2004, Michael Brines and Anthony Cerami at the Kenneth S. Warren Institute published a paper in PNAS that changed the framing. EPO’s tissue-protective effects, they showed, were not mediated by the same receptor that drives erythropoiesis. The classical EPO receptor is a homodimer — two copies of the same subunit locked together. But tissue protection runs through a different receptor entirely: a heterodimer of one EPO receptor subunit and one β-common receptor subunit (CD131). They called it the Innate Repair Receptor. The two jobs were not locked together after all — they were running through two different doors.

ARA-290 is what came through the second door. Brines and Cerami mapped the specific surface of EPO that binds the Innate Repair Receptor — a region on helix B of the EPO protein — and engineered an 11-amino-acid peptide that mimics only that surface. The result is a molecule that activates the repair receptor without touching the erythropoietic one. No red blood cells. No polycythemia. No doping risk. Just the tissue protection.

Five human clinical trials have tested ARA-290 in patients with sarcoidosis-associated nerve damage, diabetic neuropathy, and diabetic macular edema. The most important — the DOSARA trial — enrolled 64 sarcoidosis patients in a randomized, double-blind, placebo-controlled, dose-ranging study and met its primary endpoint: the 4 mg dose significantly increased corneal nerve fiber area, a direct measure of nerve regeneration. The FDA granted ARA-290 both Orphan Drug and Fast Track designations for sarcoidosis. And then, as far as public records show, the pipeline stalled. No Phase 3 trial has been announced. This article explains what ARA-290 is, what the clinical data actually shows, and why one of the most promising molecules in Cluster B has not yet crossed the finish line.

Quick Facts: ARA-290 (Cibinetide) at a Glance

What Is ARA-290?

Your body already knows how to repair damaged tissue. That knowledge lives, in part, inside erythropoietin — the same hormone that makes red blood cells. But for decades, there was no way to use EPO’s repair toolkit without also flooding the body with red blood cells — a side effect that causes blood clots and kills patients. ARA-290 is the solution: an 11-amino-acid synthetic peptide engineered from the specific surface of EPO that activates tissue repair, and only tissue repair, by targeting a receptor the classical EPO receptor cannot reach.

Its full name is cibinetide (INN), also called pHBSP — pyroglutamate helix B surface peptide. The sequence is pGlu-Glu-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, with a molecular weight of 1,257.3 Da. The pyroglutamylated N-terminus protects against aminopeptidase degradation, improving stability over a naked peptide. ARA-290 was developed by Araim Pharmaceuticals in Tarrytown, New York, co-founded by Michael Brines and Anthony Cerami — the researchers who first identified the Innate Repair Receptor.

The target is the Innate Repair Receptor (IRR), a heterodimer of the EPO receptor subunit and the β-common receptor subunit (CD131). This is distinct from the classical EPO receptor homodimer responsible for erythropoiesis. ARA-290 activates the IRR without engaging the classical EPOR. It does not stimulate red blood cell production, does not increase hematocrit, and does not carry the cardiovascular risks of EPO therapy.

The EPO Unbundling Story: Why the Drug Industry Needed a Repair Peptide Without the Blood

Erythropoietin’s tissue-protective effects were not a secret. By the late 1990s, researchers had published dozens of studies showing that EPO protected brain tissue after stroke, heart muscle after infarction, kidneys after ischemia, and peripheral nerves after injury. The mechanism appeared to be anti-apoptotic signaling — EPO told stressed cells not to die. The clinical potential was enormous.

The problem was equally enormous. EPO stimulates erythropoiesis — red blood cell production. In healthy tissue, that drives up hematocrit, increases blood viscosity, and raises the risk of thrombosis, stroke, and cardiovascular death. Clinical trials of EPO in cancer patients for anemia showed increased mortality. The protective effects and the dangerous effects appeared to be inseparable.

The Two-Receptor Insight

In 2004, Michael Brines and Anthony Cerami published a foundational paper in PNAS (PMID: 15456912) that reframed the problem. EPO’s tissue-protective effects, they demonstrated, are not mediated by the same receptor that drives erythropoiesis. The classical EPO receptor is a homodimer — two copies of the EPO receptor subunit (EPOR) locked together. This homodimer has high affinity for EPO and drives red blood cell production in the bone marrow.

But tissue protection runs through a different receptor: a heterodimer of one EPOR subunit and one β-common receptor subunit (CD131, also called the β-common subunit because it is shared with IL-3, IL-5, and GM-CSF receptors). Brines and Cerami named this the Innate Repair Receptor (IRR). The IRR has lower affinity for EPO than the classical homodimer, which is why tissue protection typically requires higher EPO concentrations — concentrations that also activate the erythropoietic receptor. The two jobs appeared linked not because they ran through the same door, but because the therapeutic window was too narrow to hit one door without hitting the other.

Naming the Receptor

In 2012, Brines and Cerami published “The Receptor That Tames the Innate Immune Response” (PMID: 22183892), formally characterizing the IRR. The receptor is expressed on neurons, macrophages, endothelial cells, Schwann cells, and cardiomyocytes — exactly the cell types involved in tissue repair and inflammation resolution. Its distribution explained why EPO’s protective effects had been observed across so many organ systems.

Engineering ARA-290

With the receptor identified, the next step was to build a molecule that could open only the repair door. Brines and Cerami mapped the specific surface region of EPO that interacts with the IRR — a stretch of amino acids on helix B of the EPO protein. In 2013, they published the design rationale (PMID: 23456859): an 11-amino-acid peptide that mimics the helix B surface geometry without replicating the full EPO structure needed to activate the classical homodimer.

This is not a random screening hit. ARA-290 was rationally designed from a structural understanding of receptor selectivity — arguably the most elegant piece of pharmaceutical design in the Cluster B portfolio. The molecule activates the Innate Repair Receptor. It does not activate the classical EPOR homodimer. The erythropoietic and tissue-protective effects of EPO have been unbundled.

Mechanism of Action

The Innate Repair Receptor

ARA-290’s primary target is the Innate Repair Receptor (IRR), a heterodimer composed of one EPO receptor (EPOR) subunit and one β-common receptor (CD131) subunit. The IRR is structurally and functionally distinct from the classical EPOR homodimer. It is expressed on neurons, macrophages, endothelial cells, Schwann cells, and cardiomyocytes — cells directly involved in tissue injury response and repair. The receptor has lower affinity for EPO than the classical homodimer, which means it requires higher local concentrations for activation. ARA-290 bypasses this issue entirely by binding selectively to the IRR without engaging the classical homodimer at any concentration.

Downstream Signaling

When ARA-290 activates the IRR, it triggers several downstream pathways relevant to tissue repair. NF-κB inhibition reduces the production of pro-inflammatory cytokines, shifting the local immune environment from damage to resolution. Anti-apoptotic signaling protects stressed cells from programmed death — buying time for repair mechanisms to restore function. In nociceptive pathways, ARA-290 modulates TRPV1 channels, integrating immune and pain signaling in a way that relieves pathophysiological pain without the sedation or addiction risk of traditional analgesics (PMID: 26774587). In the spinal cord, ARA-290 suppresses microglial activation, reducing central sensitization in neuropathic pain models (PMID: 24529189).

Perhaps most importantly, ARA-290 stimulates nerve fiber regeneration. The DOSARA trial demonstrated this directly: corneal confocal microscopy showed increased corneal nerve fiber area, and GAP-43-positive intraepidermal nerve fiber counts increased — both markers of active nerve regrowth from damaged axons. This is not neuroprotection (preventing further damage). This is neuroregenerative signaling — actual regrowth of lost nerve fibers.

What ARA-290 Does Not Do

ARA-290 does not stimulate erythropoiesis. It does not increase hematocrit or hemoglobin. It does not cause thrombotic events. It does not activate the classical EPOR homodimer. Across every human trial conducted to date, these negatives have held: hematologic parameters remained stable, with no evidence of erythropoietic stimulation at any tested dose. This is the entire therapeutic rationale — the tissue-protective effects of EPO, delivered without the blood.

Clinical Evidence: Human Trials

ARA-290 has been tested in five published human clinical trials across three indications: sarcoidosis-associated small fiber neuropathy, diabetic neuropathy, and diabetic macular edema. A sixth study explored antidepressant properties in a human neuropsychological model. The trials are generally small (22 to 64 patients) and short (4 to 12 weeks), but the signal is consistent: across different populations and different designs, ARA-290 improved nerve-related outcomes and showed a clean safety profile.

Trial 1: Sarcoidosis SFN Pilot (Heij et al. 2012)

The first human trial of ARA-290 was a randomized, double-blind, placebo-controlled pilot in 22 sarcoidosis patients with small fiber neuropathy (PMID: 23168581). Twelve patients received ARA-290 at 2 mg IV three times per week for four weeks; ten received placebo. The primary outcome was the Small Fiber Neuropathy Screening List (SFNSL) score. ARA-290 produced a significant improvement (Δ −11.5 vs. Δ −2.9 for placebo, p<0.05), along with significant gains in SF-36 pain and physical functioning domains. No drug-related adverse events were reported. The trial was small and IV-only, but it established the first proof-of-concept signal in humans.

Trial 2: Sarcoidosis SFN Open-Label Extension (Dahan et al. 2013)

An open-label, three-week IV treatment in sarcoidosis patients with refractory small fiber neuropathy (PMID: 24136731). The results showed significant improvements in neuropathic pain, increased corneal nerve fiber density measured by confocal microscopy, improved sensory pain thresholds, and improved quality of life and physical functioning. As an open-label study, it lacks the rigor of a placebo-controlled design, but the corneal nerve fiber density data was the first objective evidence that ARA-290 might be doing something structural — regrowing nerves, not just reducing symptoms.

Trial 3: Diabetic Neuropathy Phase 2 (Brines et al. 2015)

A Phase 2 trial in type 2 diabetes patients using ARA-290 at 4 mg subcutaneous daily for 28 days, with a 28-day follow-up period (PMID: 25387363). The study reported improvements in HbA1c and lipid profiles persisting through day 56. No clinically significant laboratory abnormalities were detected in hematologic, hepatic, renal, or pancreatic panels. Four serious adverse events occurred in the treatment arm, with two judged “possibly related” — though the published abstract does not fully characterize these events. Importantly, this trial validated the subcutaneous self-administration route, which became the standard for subsequent studies.

Trial 4: DOSARA Phase 2b (see dedicated section below)

The largest and most rigorous trial. Covered in full in the next section.

Trial 5: Diabetic Macular Edema Phase 2 (2020)

A Phase 2 clinical trial testing a 12-week cibinetide course in diabetic macular edema patients (PMID: 32674280). The study confirmed safety: no serious adverse events, no anti-cibinetide antibodies. This was primarily a safety and tolerability study; efficacy data was limited. The absence of anti-drug antibodies is relevant — it means the immune system does not appear to mount a neutralizing response against ARA-290, which would limit its usefulness in chronic dosing.

Trial 6: Antidepressant Properties (Kemp et al. 2015)

An exploratory study using a human neuropsychological model to test whether ARA-290 has antidepressant properties through IRR modulation (PMID: 26431906). This was a preliminary investigation, not a clinical efficacy trial for depression. It suggests a broader CNS role for the IRR but does not constitute clinical evidence for antidepressant use.

The DOSARA Trial: Phase 2b Results

The DOSARA trial — Dose-finding Study of ARA-290 in Sarcoidosis — is the centerpiece of ARA-290’s clinical evidence (PMID: 28475703). Published in PNAS in 2017, it enrolled 64 sarcoidosis patients with small fiber neuropathy and neuropathic pain in a Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging design.

Parameter	Detail
Design	Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging
Population	64 sarcoidosis patients with SFN and neuropathic pain
Intervention	Cibinetide 1 mg, 4 mg, or 8 mg SC daily for 28 days vs. placebo
Primary Endpoint	Change in corneal nerve fiber area (CNFA) at day 28
Key Result	4 mg dose met primary endpoint: placebo-corrected CNFA increase of 697 μm² (95% CI: 159–1236, p=0.012), approximately 23% increase from baseline
Secondary Findings	Significant increase in regenerating intraepidermal nerve fibers (GAP-43+)
Dose-Response	4 mg was the optimal dose; 1 mg showed less effect; 8 mg did not show clear superiority over 4 mg

Why This Trial Matters

The DOSARA trial is important for three reasons. First, it used an objective, quantifiable primary endpoint. Corneal nerve fiber area is measured by confocal microscopy — a camera, not a questionnaire. This eliminates the placebo response and subjective bias that plague symptom-based neuropathy trials. Second, the dose-response relationship (4 mg optimal, with diminishing returns at 8 mg) is the kind of pharmacological pattern that supports a real biological effect rather than noise. Third, the GAP-43-positive regenerating fiber data suggests that ARA-290 is not merely preventing further nerve loss but actively stimulating regrowth — disease modification in the truest sense.

What It Does Not Tell Us

Twenty-eight days is not enough to know whether the nerve regeneration is durable. The trial was in sarcoidosis patients — extension to other neuropathies is plausible but unproven. CNFA is a surrogate endpoint — meaningful but not a clinical outcome like walking ability or pain-free days. And 64 patients, however well the statistics work, is still a small trial by registration standards.

Preclinical Evidence

ARA-290’s preclinical portfolio is broad, spanning neuropathic pain, cardiovascular aging, cerebral ischemia, retinal disease, and islet transplantation. The common thread across all systems is the Innate Repair Receptor — the same target, activated in different tissue contexts.

Neuropathic Pain

Brines et al. (2014) demonstrated that ARA-290 produced long-term relief of neuropathic pain coupled with suppression of spinal microglia response in a rodent neuritis model (PMID: 24529189). A related study showed that ARA-290 reversed mechanical allodynia in the neuritis model (PMID: 23262243). Swartjes et al. (2016) identified TRPV1 channel targeting as a key mechanism, demonstrating integration between the immune system and nociception (PMID: 26774587).

Cardiovascular Aging and Healthspan

Feicht et al. (2023) conducted a 15-month randomized controlled trial in aged Fischer 344 × Brown Norway rats (n=192), published in Frontiers in Cardiovascular Medicine (PMID: 36741836). Rats beginning at 18 months of age (roughly equivalent to 55–60 human years) received chronic ARA-290 or saline. The treated animals showed reduced cardiac inflammation, preserved left ventricular ejection fraction, blunted age-related blood pressure elevations, preserved cardiac myocyte-to-non-myocyte ratio, and reduced infiltrating immune cells and pro-inflammatory cytokines. The study was designed as a healthspan investigation — it measured functional preservation, not lifespan extension.

Cerebral Ischemia, Retinal Disease, and Islet Transplantation

A 2024 study showed that ARA-290 exerted neuroprotective action against cerebral ischemic injury by suppressing neuronal apoptosis and inflammatory reactions in mice through the β-common receptor. Reid et al. (2019) demonstrated that cibinetide enhanced the vasoreparative potential of endothelial colony-forming cells in ischemic retina (PMID: 30876881). A 2021 study showed that cibinetide protected isolated human islets under stress and improved engraftment in an intra-portal islet transplantation model (PMID: 34498509). Additionally, ARA-290 attenuated doxorubicin-induced genotoxicity and oxidative stress in a 2020 cardioprotection study (PMID: 32335150).

Nerve Regeneration: Disease Modification versus Symptom Relief

Most neuropathic pain treatments do not fix nerves. Gabapentin, pregabalin, duloxetine, and opioids reduce pain signaling through various mechanisms, but none of them address the underlying nerve damage that generates the pain. When the drugs stop, the nerves remain damaged and the pain returns. This is symptom management, not disease modification.

Sarcoidosis-associated small fiber neuropathy has no approved disease-modifying treatment. The underlying disease process destroys small nerve fibers — the thin, unmyelinated C-fibers and thinly myelinated Aδ fibers responsible for pain, temperature sensation, and autonomic function. Once destroyed, these fibers do not spontaneously regenerate in most patients. The result is chronic neuropathic pain, numbness, and autonomic dysfunction for which current medicine offers only symptom palliation.

ARA-290’s DOSARA data changes the framing. The trial measured two structural endpoints: corneal nerve fiber area (CNFA) by confocal microscopy, and GAP-43-positive intraepidermal nerve fiber (IENF) counts in skin biopsies. GAP-43 is a marker of axonal regeneration — it is expressed specifically in growing nerve fibers, not in stable or degenerating ones. The 4 mg dose produced a 23% increase in CNFA and a significant increase in GAP-43-positive fibers. This is not pain relief. This is structural nerve regrowth measured by two independent imaging methods.

If confirmed in larger trials with longer follow-up, this would represent a fundamentally different therapeutic approach for small fiber neuropathy — fixing the underlying problem instead of covering up the symptoms. That is the clinical promise that justifies continued interest in ARA-290 despite its stalled pipeline.

Side Effects and Safety Profile

Across all published human trials involving approximately 150 or more subjects, ARA-290’s safety profile is notable for what it does not show: no erythropoietic stimulation, no clinically significant laboratory abnormalities, and no anti-drug antibodies.

Reported Adverse Effects

Side Effect	Severity	Notes
Injection site reactions	Mild	Common with SC administration
Headache	Mild, transient	Reported in some subjects
GI discomfort	Mild	Reported in some subjects
Serious adverse events (diabetic neuropathy trial)	Serious	4 SAEs in treatment arm, 2 “possibly related” — not fully characterized in published abstract
Erythropoietic stimulation	None	Hematocrit and hemoglobin stable across all trials — non-erythropoietic design confirmed
Anti-drug antibodies	None detected	Tested in DME trial (PMID: 32674280)

Theoretical Concerns

Cancer risk: EPO receptors are expressed on some tumor types. While ARA-290 targets the IRR rather than the classical EPOR, any compound engaging EPOR-containing receptor complexes warrants long-term cancer surveillance data that does not yet exist. This is a theoretical concern based on receptor biology, not an observed finding in any ARA-290 study.

Cardiovascular effects: Any agent acting on vascular endothelium through EPO-related receptors raises questions about endothelial function and coagulation, particularly in patients with pre-existing cardiovascular disease. No cardiovascular adverse signals have been detected in trials to date, but all trials were short-term.

Long-term safety: All human trials are 4 to 12 weeks in duration. No data exists on chronic use safety, drug-drug interactions, or reproductive and developmental toxicity in humans.

Anti-Doping Status

ARA-290’s WADA status is complicated. The compound is derived from erythropoietin and binds an EPO-receptor-containing complex. WADA’s Prohibited List includes EPO receptor agonists under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). By structure and receptor target, ARA-290 could fall under this prohibition.

The complication is that ARA-290 does not do what WADA cares about in the EPO context. It does not stimulate red blood cell production. It does not increase hematocrit. It does not enhance oxygen-carrying capacity. The performance-enhancing mechanism that drove EPO’s prohibition — blood doping — is entirely absent from ARA-290’s pharmacology. However, ARA-290 has not been individually assessed by WADA, and the Prohibited List uses broad language that may encompass it regardless of its non-erythropoietic nature.

Recommendation for athletes: Until WADA provides explicit guidance on ARA-290 or similar non-erythropoietic EPO-derived peptides, athletes subject to anti-doping testing should assume ARA-290 is prohibited.

Legal and Regulatory Status

Category	Status
FDA Approval	Not approved for any indication
FDA Orphan Drug Designation	Yes — sarcoidosis (granted 2016). Provides 7-year market exclusivity upon approval, tax credits for trial costs, and FDA protocol assistance.
FDA Fast Track Designation	Yes — sarcoidosis-associated small fiber neuropathy
Clinical Stage	Phase 2 complete; end-of-Phase-2 FDA meeting completed; Phase 3 not initiated
DEA Scheduling	Not a controlled substance. Not scheduled.
Compounding Availability	Not available from 503A/503B compounding pharmacies. Available from select research peptide suppliers.
International Approvals	None in any jurisdiction

It is important to understand what FDA Orphan Drug and Fast Track designations mean — and what they do not mean. These designations facilitate clinical development. They reflect FDA’s recognition of an unmet medical need in sarcoidosis. They do not constitute approval, endorsement of efficacy, or authorization for marketing or therapeutic claims. ARA-290 remains an investigational compound.

Common Claims versus What the Evidence Shows

Claim	What the Evidence Shows	Verdict
“ARA-290 regenerates damaged nerves”	DOSARA Phase 2b (n=64) showed significant CNFA increase at 4 mg (p=0.012) and increased GAP-43+ regenerating fibers in sarcoidosis SFN. Open-label extension confirmed corneal nerve density increases.	Supported
“ARA-290 treats neuropathic pain”	Pilot RCT (n=22) showed significant SFNSL improvement. Open-label showed neuropathic pain improvement. Preclinical models show allodynia reversal and microglial suppression.	Supported
“ARA-290 is safer than EPO for tissue repair”	Across 150+ clinical trial subjects, no erythropoietic stimulation observed. Hematocrit and hemoglobin stable. No anti-drug antibodies. Non-erythropoietic design validated — but only in short-term trials.	Supported
“ARA-290 can treat diabetic neuropathy”	Phase 2 trial showed HbA1c and lipid improvements, but the study was not primarily powered for neuropathy outcomes. DOSARA was in sarcoidosis, not diabetes.	Mixed Evidence
“ARA-290 protects the heart”	Preclinical only. Feicht et al. 2023 showed cardiac protection in aged rats over 15 months. Doxorubicin cardioprotection in animals. No human cardiac trials.	Preclinical Only
“ARA-290 can treat stroke”	One mouse model (2024) showed neuroprotection against cerebral ischemia. No human data.	Preclinical Only
“ARA-290 improves eye disease”	Phase 2 in diabetic macular edema showed safety but limited efficacy data. Preclinical retinal ischemia data (Reid 2019).	Mixed Evidence
“ARA-290 extends lifespan”	Feicht 2023 showed healthspan preservation (cardiac function, inflammation) in aged rats — NOT lifespan extension. No human longevity data.	Unsupported
“ARA-290 has no side effects”	Clinical safety profile is generally clean, but 2 SAEs “possibly related” in diabetic neuropathy trial were not fully characterized. All trials were short-term. Long-term safety unknown.	Mixed Evidence
“ARA-290 is the same as EPO”	ARA-290 is an 11-aa peptide derived from one surface region of EPO. It does NOT replicate EPO’s erythropoietic effects. Structurally, functionally, and pharmacologically distinct from EPO, darbepoetin, and other ESAs.	Unsupported
“ARA-290 is FDA-approved”	ARA-290 has FDA Orphan Drug and Fast Track designations — these are NOT approvals. They facilitate development but do not authorize marketing or therapeutic claims.	Unsupported
“ARA-290 is widely available for self-administration”	ARA-290 is not available from compounding pharmacies and has extremely limited availability from research peptide suppliers. Primarily an investigational compound.	Unsupported

Dosing in Published Research

Trial	Route	Dose	Frequency	Duration
Sarcoidosis SFN Pilot (2012)	IV	2 mg	3×/week	4 weeks
Sarcoidosis SFN Extension (2013)	IV	Not specified	3×/week	3 weeks
Diabetic Neuropathy Phase 2 (2015)	SC	4 mg	Daily (self-administered)	28 days + 28-day follow-up
DOSARA Phase 2b (2017)	SC	1, 4, or 8 mg	Daily	28 days
Diabetic Macular Edema (2020)	SC (presumed)	Not specified	—	12 weeks

The IV-to-SC transition between early and later trials suggests Araim validated subcutaneous self-administration for outpatient use. The 4 mg SC daily dose was the Phase 2b sweet spot — it met the primary endpoint while 1 mg showed less effect and 8 mg showed no clear superiority. All trials were short (3 to 12 weeks), and no long-term dosing data exists.

Dosing in Self-Experimentation Communities

The limited community reports that exist generally mirror published clinical data: 2 to 4 mg subcutaneous daily, reconstituted from lyophilized powder with bacteriostatic water. No standardized community protocol exists. Reddit and peptide forum discussions are sparse compared to mainstream compounds in the self-experimentation space.

Preparation and Storage

Research-grade ARA-290 is typically supplied as lyophilized powder. Standard peptide reconstitution applies: add bacteriostatic water slowly along the vial wall, allow the powder to dissolve without shaking. Store lyophilized powder at −20°C for long-term or 2–8°C for short-term storage. Once reconstituted, store at 2–8°C and use within two to four weeks. Protect from light. Use sterile technique with clean vials and insulin syringes.

Combination Protocols

No published data exists on combining ARA-290 with other Cluster B peptides. The theoretical considerations are limited to mechanism-level reasoning:

ARA-290 + BPC-157: Different mechanisms (IRR activation vs. VEGF and growth factor pathways). Theoretical complementarity for tissue repair, but entirely speculative. No published interaction data.

ARA-290 + TB-500: Different mechanisms (IRR activation vs. actin polymerization and cell migration). No data on combined use.

ARA-290 + EPO: Conceptually counterproductive. ARA-290 was designed to provide EPO’s tissue-protective effects without the erythropoietic effects. Adding EPO to ARA-290 reintroduces the exact risks ARA-290 was engineered to avoid.

Any combination protocol you encounter online is invented, not evidence-based. The absence of interaction data means unknown risk.

The Stalled Pipeline: Why Phase 3 Never Happened

ARA-290 completed Phase 2b with a positive primary endpoint. The FDA granted both Orphan Drug and Fast Track designations. An end-of-Phase-2 meeting with the FDA was completed — the regulatory equivalent of being told, “We see the data, here is what your Phase 3 needs to look like.” By every conventional measure, this compound was ready for the next step. And then, as far as publicly available information shows, the pipeline went quiet.

This is the “valley of death” in pharmaceutical development. Phase 2 trials cost millions. Phase 3 trials cost tens of millions to hundreds of millions. They require hundreds to thousands of patients across multiple clinical sites, GMP manufacturing at commercial scale, years of follow-up, and regulatory filings that run to tens of thousands of pages. For a small biotech company like Araim Pharmaceuticals, these costs require either a major pharmaceutical partner willing to license or co-develop the asset, or substantial institutional investment from venture capital or public markets.

Sarcoidosis is a rare disease, which limits the commercial market size even if ARA-290 succeeds. The Orphan Drug designation provides incentives — seven years of market exclusivity, tax credits, regulatory fee waivers — but these incentives are designed to make rare disease development possible, not profitable in the way that a mass-market drug would be. A blockbuster pain drug might generate billions in revenue. An orphan neuropathy drug for a subset of sarcoidosis patients is a different commercial proposition entirely.

This is a pattern the peptide world needs to understand. A positive Phase 2b result in a small biotech does not guarantee a drug. It guarantees an expensive next step that the company may not be able to afford. ARA-290’s stalled pipeline is not evidence against the molecule — it is evidence of the funding gap that kills promising compounds before they can prove themselves. The science here is real. The question is whether the money follows.

Frequently Asked Questions

Related Compounds: How ARA-290 Compares

ARA-290 occupies a unique position in Cluster B. It is the only compound with multiple controlled human clinical trials, including a positive Phase 2b primary endpoint. Its mechanism — selective IRR activation — is entirely distinct from the growth factor pathways, actin dynamics, or immune modulation that characterize its Cluster B peers.

BPC-157

The most popular peptide in the injury recovery space, with a preclinical portfolio spanning over 100 rodent models. But its human evidence is limited to three uncontrolled studies. Where ARA-290 has a positive Phase 2b RCT, BPC-157 has not yet completed one. Different mechanisms entirely — BPC-157 works through VEGF and growth factor pathways, ARA-290 through the Innate Repair Receptor.

TB-500

A synthetic fragment of Thymosin β4, used in veterinary medicine and widely adopted in the self-experimentation community. Zero human clinical trials. Its mechanism (actin polymerization, cell migration) is entirely different from ARA-290’s IRR activation. TB-500’s popularity is driven by availability and anecdotal reports, not clinical evidence.

GHK-Cu

Primarily studied as a topical compound for skin and wound healing. The injectable and systemic evidence base is minimal. Its copper-peptide mechanism is unrelated to ARA-290’s EPO-derived repair signaling.

KGF / Palifermin

The only FDA-approved compound in Cluster B (for oral mucositis in stem cell transplant patients). Tier 1, but approved for a single narrow indication. Growth factor mechanism (FGFR2b) is distinct from ARA-290’s IRR activation. Palifermin proves that Cluster B peptides can reach FDA approval — through an orphan indication, just like ARA-290 is attempting.

PRP (Platelet-Rich Plasma)

Not a peptide but an autologous blood-derived growth factor concentrate with extensive clinical use in orthopedics and dermatology. Tier 2 like ARA-290, but a fundamentally different class — PRP contains hundreds of growth factors derived from the patient’s own blood, whereas ARA-290 is a single synthetic peptide with a defined molecular target.

Summary and Key Takeaways

ARA-290 (cibinetide) is a rationally designed peptide with the strongest clinical evidence of any compound in the Cluster B injury recovery portfolio. Its story — from Brines and Cerami’s foundational receptor biology through five human trials to a stalled Phase 3 — is a case study in both the promise and the practical limitations of small-molecule peptide therapeutics.

Key Takeaways

1. ARA-290 is a rationally designed peptide — engineered from the tissue-protective surface of erythropoietin to activate the Innate Repair Receptor without stimulating red blood cell production. The science behind it is grounded in 20-plus years of Brines and Cerami’s foundational research.
2. It has the strongest clinical evidence in Cluster B — five human trials, including a Phase 2b RCT (DOSARA, n=64) that met its primary endpoint with a statistically significant result (p=0.012). No other Cluster B compound comes close to this evidence base.
3. The DOSARA data suggests disease modification — nerve fiber regeneration measured by corneal confocal microscopy and GAP-43-positive IENF counts, not just symptom relief. If confirmed in larger trials, this would represent a fundamentally different approach to neuropathic pain.
4. The safety profile is clean but limited — no erythropoietic stimulation across 150-plus subjects, mild side effects, no anti-drug antibodies. But all trials are short (4 to 12 weeks) and long-term safety is unknown.
5. The pipeline has stalled — despite positive Phase 2b data, FDA Orphan Drug and Fast Track designations, and a completed end-of-Phase-2 meeting, no Phase 3 trial has been announced. This is a funding gap problem, not a science problem.
6. Community adoption is minimal — ARA-290 is not widely available from peptide vendors and has almost no self-experimentation community presence. It remains primarily an investigational compound.
7. ARA-290 is a Reasonable Bet — the mechanistic foundation is solid, the clinical signal is consistent, and the disease-modifying evidence is genuinely promising. But it remains an unfinished story — a compound that proved itself in Phase 2 and then ran out of runway.

Verdict Recapitulation

ARA-290 earns Tier 2 (Clinical Trials) and a Reasonable Bet verdict on the strength of five human clinical trials, a Phase 2b RCT that met its primary endpoint, disease-modifying surrogate data, FDA regulatory designations, and a coherent mechanistic foundation spanning two decades of research. The pipeline stall is a commercial reality, not a scientific failure. If Phase 3 funding materializes, ARA-290 has a legitimate path to becoming the first disease-modifying treatment for sarcoidosis-associated small fiber neuropathy.

Where to Source ARA-290

Further Reading and Resources

If you want to go deeper on ARA-290, the evidence landscape for injury recovery and tissue repair peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

On Peptidings

• BPC-157 — The most-studied repair peptide in preclinical models, with extensive but uncontrolled human evidence
• TB-500 (Thymosin Beta-4) — Veterinary-origin repair peptide with zero human trials but broad community adoption
• KGF / Palifermin — The only FDA-approved compound in Cluster B, for oral mucositis
• PRP (Platelet-Rich Plasma) — Autologous growth factor concentrate with extensive clinical use
• About Peptidings — Our editorial methodology and evidence framework
• Evidence Framework — How we assign evidence tiers and verdicts

External Resources

• PubMed — Biomedical Research Database — Search for “ARA-290,” “cibinetide,” or “pHBSP”
• ClinicalTrials.gov — Check for registered or ongoing cibinetide trials

Selected References and Key Studies

Human Clinical Trials

1. Heij L, et al. “Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.” Mol Med. 2012;18:1430-1436. PubMed
2. Dahan A, et al. “ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.” Mol Med. 2013;19:334-345. PubMed
3. Brines M, et al. “ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.” Mol Med. 2015;20:658-666. PubMed
4. Brines M, et al. “Cibinetide, a rationally designed EPO-derived compound, is regenerative in sarcoidosis subjects with small nerve fiber loss.” PNAS. 2017;114(41):E8817-E8826. PubMed
5. Brines M, et al. “Cibinetide Phase 2 clinical trial in diabetic macular edema.” 2020. PubMed
6. Kemp AH, et al. “ARA 290 antidepressant properties in human neuropsychological model.” 2015. PubMed

Preclinical Studies

7. Brines M, et al. “ARA 290 produces long-term relief of neuropathic pain coupled with suppression of spinal microglia.” Pain. 2014. PubMed
8. Brines M, et al. “ARA 290 reversed mechanical allodynia in the neuritis model.” 2013. PubMed
9. Swartjes M, et al. “ARA 290 relieves pathophysiological pain by targeting TRPV1 channel.” 2016. PubMed
10. Feicht SE, et al. “A non-erythropoietic innate repair receptor agonist extends healthspan and preserves cardiac function in the aging rat.” Front Cardiovasc Med. 2023. PubMed
11. “ARA-290 attenuated doxorubicin-induced genotoxicity and oxidative stress.” 2020. PubMed
12. Reid E, et al. “Cibinetide enhanced vasoreparative potential of endothelial colony-forming cells in ischemic retina.” 2019. PubMed
13. “Cibinetide protected isolated human islets under stress and improved engraftment.” 2021. PubMed

Foundational and Mechanistic

14. Brines M, et al. “Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor.” PNAS. 2004;101:14907-14912. PubMed
15. Brines M, Cerami A. “The receptor that tames the innate immune response.” Mol Med. 2012;18:486-496. PubMed
16. Brines M, Cerami A. “Erythropoietin and engineered innate repair activators.” Methods Mol Biol. 2013;982:1-11. PubMed
17. Brines M, Cerami A. “Targeting the innate repair receptor to treat neuropathy.” Drug Des Devel Ther. 2018;12:1469-1477. PubMed

---